Skip to content
Screener

Total Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$65.32B-15.4%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$1.66B-28.5%
Cytokinetics logo
CytokineticsCYTK
$2.1B+31.6%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$3.05B+7.3%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$214.9M+312%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$46.51M-7.0%

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$4.78B+236%
Enterprise value$4.75B+244%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:09 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056713
AssetsAs of / March 31, 2026 / (unaudited)As of / December 31, 2025
Operating lease liability, current portion1,0171,014
Total current liabilities22,54327,370
Operating lease liability, net of current portion2,7762,976
Total liabilities25,31930,346
Commitments and contingencies (see note 5)
Stockholders' equity:
Preferred stock, $.0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of March 31, 2026 and December 31, 2025
Common stock, $.0001 par value per share; 1,000,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 107,481,522 shares and 106,249,579 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively1010

Item 1. Financial Statements (Unaudited)

FAQ

What is Edgewise Therapeutics, Inc.'s total liabilities?
Edgewise Therapeutics, Inc. (EWTX) reported total liabilities of $25.32M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s total liabilities changed year-over-year?
Edgewise Therapeutics, Inc.'s total liabilities increased by 2.6% year-over-year, from $24.67M to $25.32M.
What is the long-term trend for Edgewise Therapeutics, Inc.'s total liabilities?
Over 5 years (2020 to 2025), Edgewise Therapeutics, Inc.'s total liabilities has grown at a 47.5% compound annual growth rate (CAGR), from $4.34M to $30.35M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Edgewise Therapeutics, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude